0.5 C
Glasgow
Tuesday, February 17, 2026
spot_img

More News

SPT Labtech and BellBrook Labs introduce high-throughput screening platform for cancer research

Jim Cornall -
SPT Labtech and BellBrook Labs have announced a collaboration to advance cancer research. Together, the companies have developed a...

Soin Neuroscience and Lilac Biosciences to collaborate to study RNA signatures in pain and neuromodulation

Jim Cornall -
Lilac Biosciences, a biotechnology company spun out of the Giuliani RNA Center at Brown University, which develops quantitative RNA-based...

Base to Base biotech podcast 46: Endometriosis and closing care gaps

Jim Cornall -
The conversations on this week’s podcast are with Vibhor Gupta, director and founder of Pangaea Data, and endogene.bio CEO...

Calla Lily Clinical Care and Merck to collaborate on intravaginal drug delivery platform

Jim Cornall -
Calla Lily Clinical Care and Merck have entered a strategic collaboration to support the continued development of Callavid, a...

Body’s own defence may be the key to longer cancer survival

Jim Cornall -
The findings from a large study led by the University of Helsinki highlight how certain ovarian cancer cells can...

Zonsen PepLib Biotech to collaborate with Lilly

Jim Cornall -
Zonsen PepLib Biotech Inc. (PepLib) has entered a global research and development collaboration and license agreement with Eli Lilly...

World-first personalised paediatric mRNA cancer vaccine trial

Jim Cornall -
Canadian company Providence Therapeutics is supporting a world-first clinical trial evaluating personalised mRNA cancer vaccines for children with advanced...

Orphan Drug Designation for cholangiocarcinoma treatment

Jim Cornall -
Partner Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD)...

Yeast cells can be used for rapid testing of cancer immunotherapy

Jim Cornall -
An international research team with strong participation from the Technical University of Denmark (DTU) has developed a new biotechnological...

Pfizer injectable shows continued weight loss in phase 2b trial

Jim Cornall -
Pfizer Inc. has announced positive topline results from its phase 2b VESPER-3 study investigating monthly maintenance dosing of its...

Skin damage protein ID could lead to new therapies

Jim Cornall -
Radiotherapy is one of the main treatment forms for cancer. Among its most common side effects is skin damage,...

Origami Therapeutics and Ipsen to advance protein degrader programme

Jim Cornall -
Origami Therapeutics, a biotech company developing small molecule protein degraders and conformation correctors to treat neurodegenerative diseases, has announced...

IQVIA and Boehringer Ingelheim announce data collaboration

Jim Cornall -
IQVIA has announced a strategic long-term collaboration with Boehringer Ingelheim. Boehringer Ingelheim has selected IQVIA’s Data-as-a-Service (DaaS+) technology offering...

Next-generation biopreservation for cell therapy

Jim Cornall -
CaseBioscience has launched CaseCryo CTG DMSO, a next-generation cryopreservation solution developed to support clinical cell therapy development, at Advanced...

Predicting cancer evolution

Jim Cornall -
Predicting tumour progression is one of the major challenges in oncology. Scientists at the University of Geneva (UNIGE) and...

Base to Base biotech podcast 45: Chronic pain, urology, Affibody molecules and radioligand therapy

Jim Cornall -
This week, we chat with Affibody CEO David Bejker, and Martin Gleave, founder and chief medical officer at Sustained...

Johnson & Johnson prostate cancer drug receives CHMP positive opinion

Jim Cornall -
Johnson & Johnson has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Breakthru Medicine emerges from stealth to develop cancer drugs

Jim Cornall -
Breakthru Medicine has emerges from stealth with the close of a $60m Series A financing round following a prior...

FDA Rare Pediatric Disease designation for mucopolysaccharidosis Type II treatment

Jim Cornall -
Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, has announced that the U.S. Food and...

CIRM approves $100m plan to accelerate genetic therapies for patients with rare diseases

Jim Cornall -
The California Institute for Regenerative Medicine (CIRM) has approved a new funding programme to accelerate therapies for rare diseases,...

Researchers develop more reliable platform to test antibody medicines

Jim Cornall -
An international research consortium, led by scientists at VIB and UGent in Belgium, has developed a new platform that...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media